Gilead's M&A streak carries on with buyout of private PARP1, autoimmune biotech

Kyle LaHucik

Senior Reporter

Gilead’s dealmaking spree, part of biopharma’s “blistering” M&A this year, continued on Tuesday with a consummation of oncology and inflammation startup XinThera.

After deals …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gilead's M&A streak carries on with buyout of private PARP1, autoimmune biotech

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Gilead­'s M&A streak car­ries on with buy­out of pri­vate PARP1, au­toim­mune biotech

Senior Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Gilead's M&A streak carries on with buyout of private PARP1, autoimmune biotech